[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Societa Italiana di Dermatologia Medica, Chirurgica, Estetica e di Malattie Sessualmente Trasmesse\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":105},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,65,83],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100608669","cerave-effect-on-restoring-skin-hydration-as-maintenance-regimen-in-subjects-with-mild-to-moderate-atopic-dermatitis-100608669",false,"NCT07204561","CeraVe Effect on Restoring Skin Hydration as Maintenance Regimen in Subjects With Mild to Moderate Atopic Dermatitis","Analysis of the CeraVe Emollient Effect on Restoring the Hydration of the Skin Barrier as Maintenance Regimen in Subjects With Mild to Moderate Atopic Dermatitis","DA_CeraVe","Inclusion criteria:\n\nSubjects with clinically confirmed mild-to-moderate atopic dermatitis (AD), as defined by an Eczema Area and Severity Index (EASI) score of 1-21, whose lesions will clear after treatment with a steroid and who will experience at least a 90% reduction in their EASI score.\n\n\\- Participants of any gender, aged 18 years or over, from any phototype or ethnic group.\n\nParticipants must be willing and able to give informed consent to participate in the study.\n\nExclusion criteria:\n\n* Age \\\u003C18 years. Participants who are unwilling or unable to give informed consent to participate in the study.\n* Receiving any systemic treatment for atopic dermatitis (AD), including corticosteroids, cyclosporine, any approved biologics or JAK inhibitors.\n* Any dermatological disorder which, in the investigator's opinion, may interfere with the accurate evaluation of the subject's skin characteristics (except AD).","ALL","18 Years","99 Years",{"count":21,"type":22},98,"ESTIMATED","INTERVENTIONAL",[25],"NA","This is an open-label, randomised, comparative, prospective, interventional study of a cosmetic product.",[28],"Atopic Dermatitis (AD)","RECRUITING","2025-09-24",{"date":32,"type":33},"2025-10-02","ACTUAL",{"date":35,"type":33},"2025-03-25",{"date":37,"type":22},"2026-07",{"name":39,"class":40},"Societa Italiana di Dermatologia Medica, Chirurgica, Estetica e di Malattie Sessualmente Trasmesse","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":52,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":41},"100540168","national-register-of-moderate-and-severe-adult-atopic-dermatitis-100540168","NCT06313333","National Register of Moderate and Severe Adult Atopic Dermatitis","Registro Nazionale Della Dermatite Atopica Moderata e Severa Nell'Adulto","ATOPYREG","Inclusion Criteria:\n\n1. Age 18 years\n2. Signature of informed consent\n3. Diagnosis of moderate and\u002For severe DA by a dermatologist specialist defined on the basis of following criteria (10):\n\n   * EASI 16\n   * EASI \\\u003C16 but with at least one of the following conditions:\n\n     1. location in at least one of the following \"critical\" locations: face, hands, genitals\n     2. QID \\> 10\n     3. VAS itching \\> 7\n     4. VAS sleep \\> 7\n\nExclusion Criteria:\n\n1. Patient unable to provide informed consent prior to any collection procedures data on the study;\n2. unable to complete the procedures required for the study;\n3. a patient already participating in another follow-up register of the same disease.",{"count":51,"type":22},1500,"10 Years","OBSERVATIONAL","Collect clinical history and treatment data of AD in adulthood;",[56],"Atopic Dermatitis","2025-06-09",{"date":59,"type":33},"2025-06-12",{"date":61,"type":33},"2020-06-15",{"date":63,"type":22},"2030-12-31",{"name":39,"class":40},{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":77,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":41},"100539899","retrospective-and-prospective-observational-study-in-patients-with-advanced-basal-cell-carcinoma-100539899","NCT06309836","Retrospective and Prospective Observational Study in Patients With Advanced Basal Cell Carcinoma","REGISTRO-BCC","Inclusion Criteria:\n\n1. Male and female patients aged ≥ 18 years\n2. Patients diagnosed with advanced basal cell carcinoma of the skin, i.e. tumours included in at least one of the following categories: locally advanced carcinoma (not radically treatable by surgery and\u002For radiotherapy), carcinoma with lymph node and\u002For distant metastatic localisation\n3. patients who have had at least one access (first visit or follow-up visit) at the dermatology or oncology outpatient clinic of the centres involved\n\n   * Patients diagnosed with advanced BCC who have accessed the centre from 1 January 2016 until the date of activation of the centre will be included in the retrospective cohort;\n   * Patients diagnosed with advanced BCC who have accessed the centre from the date of activation\n4. Signature of informed consent\n\nExclusion Criteria:\n\nPatients incapable of giving informed consent",{"count":73,"type":22},250,"Retrospective and Prospective Observational Study in Patients With Advanced Basal Cell Carcinoma.",[76],"Basal Cell Carcinoma",{"date":59,"type":33},{"date":79,"type":33},"2021-06-23",{"date":81,"type":22},"2029-12-31",{"name":39,"class":40},{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":23,"phases":93,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":41},"100582858","study-on-the-effectiveness-of-an-emollient-cream-containing-pre-and-postbiotic-and-niacinamide-4-in-the-treatment-of-skin-xerosis-and-itching-in-oncological-patients-treated-with-anti-egfr-100582858","NCT06868771","Study on the Effectiveness of an Emollient Cream Containing Pre and Postbiotic and Niacinamide 4% in the Treatment of Skin Xerosis and Itching in Oncological Patients Treated with Anti-EGFR","Studio Sulla Efficacia Di Una Crema Emolliente Contenente Pre E Postbiotici E Niacinamide 4% Nel Trattamento Della Xerosi Cutanea E Del Prurito in Pazienti Oncologici in Trattamento Con Anti-EGFR","PENSANTE","Inclusion Criteria:\n\n1. patients aged 18 who have been receiving anti-EGFR therapy for more than three months,\n2. signature of the informed consent.\n\nExclusion Criteria:\n\n1. Patients diagnosed with Grade II papulopustulous skin reaction according to the Common Terminology Criteria for Adverse Event (CTCAE) scale at the time of enrolment;\n2. concomitant use of emollients and\u002For steroidal creams;\n3. personal history of xerotic pathologies (e.g. lichen, ichthyosis) and\u002For itching of n.d.d.;\n4. inability to provide informed consent or inability to complete the procedures required for enrollment in the study.",{"count":92,"type":22},164,[25],"Study on the Effectiveness of an Emollient Cream Containing Pre and Postbiotic and Niacinamide 4% in the Treatment of Skin Xerosis and Itching in Oncological Patients Treated With Anti-EGFR.",[96],"Xerosis Cutis","2025-03-04",{"date":99,"type":33},"2025-03-11",{"date":101,"type":33},"2022-07-29",{"date":103,"type":22},"2025-04-30",{"name":39,"class":40},""]